Pharma News, 2021

Pfizer Inc. asked U.S. regulators for emergency-use authorization of its Covid-19 pill that could play a critical role in further protecting high-risk patients from the disease’s worst effects. ...

A Rice University undergraduate student’s grit and talent paid off in a big way when she introduced the first synthesis of a rare and potentially potent molecule drawn from poppies.  ...

NICE has issued a positive recommendation for Arvelle Therapeutics’ cenobamate (Ontozry), for the treatment of focal-onset seizures in adults with uncontrolled epilepsy in England and Wales. ...

The Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application to trehalose (SLS-005; Seelos Therapeutics, New York, NY) for spinocerebellar ataxia (SCA) treatme...

Today, the U.S. Food and Drug Administration approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera, a blood disease that causes the overproduction of red...

"They have literally cost millions of lives,” Albert Bourla said in an interview with the Atlantic Council.

Europe's drug regulator has recommended two COVID-19 antibody therapies - one from American-Swiss partners Regeneron-Roche and another from South Korea's Celltrion, as the region builds up its defe...

World Diabetes Day provides an opportunity to raise awareness of diabetes as a global public health issue and what needs to be done, collectively and individually, for better prevention, diagnosis...

Prexasertib has been on a more than two decade journey, and that doesn't include commercialization. 

Producers of adenovirus-vectored COVID-19 vaccines have had to deal with more questions about rare side effects than those making mRNA COVID-19 vaccines.

Organon, and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused ...

The European Commission (EC) has approved an agreement for Valneva to supply up to 60 million doses of the company’s inactivated COVID-19 vaccine candidate VLA2001 over a period of two years. ...